As CD8+ NK cells seem to have a high cytotoxic function against tumor cells, we analyzed this subset of NKs in patients treated with R-GDP plus lenalidomide in the R2-GDP-GOTEL phase II trial and evaluated their prognostic impact at baseline. The gene discussed is CD8A; the disease is neoplasm.